The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Sep. 16, 2021
Applicant:

Cellular Biomedicine Group HK Limited, Hong Kong, CN;

Inventors:

Yutian Wei, Hong Kong, CN;

Lin Zhu, Hong Kong, CN;

Yanfeng Li, Hong Kong, CN;

Yihong Yao, Hong Kong, CN;

Xin Yao, Hong Kong, CN;

Jiaqi Huang, Hong Kong, CN;

Li Zhang, Hong Kong, CN;

Shigui Zhu, Hong Kong, CN;

Xiaoteng Lv, Hong Kong, CN;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01);
Abstract

The present invention provides a BCMA-targeted chimeric antigen receptor (CAR) as well as a preparation method therefor and an application thereof. Specifically, the present invention provides the BCMA-targeted CAR, which comprises a BCMA-targeted scFv, a hinge region, a transmembrane region, and an intracellular signal structure domain. The present invention provides a nucleic acid molecule for coding the CAR and a corresponding expression vector as well as CAR-T cells and application thereof. The CAR of the present invention targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.


Find Patent Forward Citations

Loading…